All In Biotech

Drug Trial Radar · NCT05549297

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)

Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Dec 19, 2022

Primary completion

Mar 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Immunocore LtdIndustry
Sponsor type
Industry
First posted
Sep 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.

Conditions

  • Advanced Melanoma

Interventions

  • TebentafuspDrug

    Soluble gp100-specific T cell receptor with anti-CD3 scFV

  • Tebentafusp with PembrolizumabDrug

    Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab

  • Investigators ChoiceDrug

    Investigators choice of therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to ~4 years

Locations

82 sites in 12 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • University of Kansas Cancer Center - Westwood

    Westwood, Kansas · Recruiting

  • St Elizabeth Healthcare (St Elizabeth Medical Center)

    Edgewood, Kentucky · Recruiting

  • St Elizabeth Healthcare (St Elizabeth Medical

    Edgewood, Kentucky · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Minnesota Medical Center

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic Minnesota

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Northwell Health Cancer Institute - Zuckerberg Cancer Center

    Lake Success, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • OU Health Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Thomas Jefferson University Medical Oncology Clinic

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Gibbs Cancer Center and Research Institute

    Spartanburg, South Carolina · Recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Recruiting

  • Houston Methodist Hospital/Houston Methodist Cancer Center

    Houston, Texas · Recruiting

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Melanoma Institute Australia

    Wollstonecraft, New South Wales, Australia · Recruiting

  • Gallipoli Medical Research Foundation (GMRF)

    Greenslopes, Queensland, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Alfred Health

    Melbourne, Victoria, Australia · Recruiting

  • LKH - Universitaetsklinikum Graz

    Graz, Austria · Recruiting

  • Kepler Universitätsklinikum

    Linz, Austria · Recruiting

  • Universitatsklinik fur Innere Medizin 3

    Salzburg, Austria · Recruiting

  • AKH - Medizinische Universität Wien

    Vienna, Austria · Recruiting

  • Cliniques Universitaires Sain-Luc

    Brussels, Belgium · Recruiting

  • UZ Brussel

    Jette, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • BC Cancer

    Vancouver, British Columbia, Canada · Recruiting

  • Princess Margaret Hospital

    Toronto, Ontario, Canada · Recruiting

  • Lady Davis Institute for Medical Research (LDI) Jewish General Hospital (JGH)

    Montreal, Quebec, Canada · Recruiting

  • CHU de Bordeaux - Hopital Saint Andre

    Bordeaux, France · Recruiting

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.